Danazol improves thrombocytopenia in HCV patients treated with peginterferon and ribavirin
Journal Title: Annals of Hepatology - Year 2011, Vol 10, Issue 4
Abstract
Background. Thrombocytopenia is a common hematologic disorder observed in patients with chronic hepatitis C virus (HCV) infection. Combined peginterferon (PEG-INF) and ribavirin treatment may exacerbate thrombocytopenia in patients with HCV. Objective. The aim of this pilot clinical trial was to assess the efficacy, tolerability and safety of Danazol in thrombocytopenia associated with PEG-INF and ribavirin treatment in patients with HCV. Material and methods. We included patients whose platelets were < 90,000/mm3 and who were undergoing antiviral treatment. Danazol (300-600 mg/day) was administered during and until the end of antiviral therapy [7.6 months (2 to 11 months)]. The monitoring was performed through platelet analysis and liver function tests. A viral load test was done at the beginning and end of treatment. Fortynine patients receiving a combined therapy of PEG-INF, ribavirin and Danazol increased their platelet levels to 121,081/mm3 (46,000-216,000/mm3); 10.6% of patients gained > 100,000 platelets/mm3, and 71% of patients maintained their initial platelet levels. Sustained viral response (SVR) was achieved in 63% of patients. SVR rates were high in patients with genotype non 1 (78.7%) and decreased in patients with genotype 1 (60.1%). The increase in platelet levels was associated to an increase in fibrinogen levels and a decrease in the activity of ALT. By contrast, patients without SVR presented a delayed response to increased platelet levels and showed no significant improvement in liver function when they received Danazol. Conclusion. Danazol can be used along with PEG-INF and ribavirin to treat thrombocytopenia in patients with HCV.
Authors and Affiliations
Guillermo Álvarez, Diana Gómez-Galicia, Lourdes Rodríguez-Fragoso, Vicente Marina, Luis Dorantes, Miguel Sánchez-Alemán, Nahum Méndez-Sánchez, Jorge Esparza
Keywords
Related Articles
- EP ID EP78076
- DOI -
- Views 139
- Downloads 0
Reply to contribution on the topic of hypovitaminosis D in chronic hepatitis C
Dress syndrome and fulminant hepatic failure induced by lamotrigine
Lamotrigine is a non-aromatic antiepileptic drug. Drug rash with eosinophilia and systemic symptoms (DRESS) syndrome is a severe idiosyncratic reaction to drugs, especially anti-epileptic drugs. Associated clinical featu...
Annual Meeting of the Mexican Association pf Hepatology
Risk factors contributing to early infection following transjugular intrahepatic portosystemic shunt in perioperative period
Introducción and aim. To investigate and identify the risk factors associated with early infection following a transjugular intrahepatic portosystemic shunt (TIPS)procedure in perioperative period. Material and methods....
Chemerin, retinol binding protein-4, cytokeratin-18 and transgelin-2 presence in sera of patients with non-alcoholic liver fatty disease
Background. Chemerin and retinol binding protein-4 (RBP-4) are adipokines which may play a role in the progression of NAFLD. Ithas been also suggested that cytokeratin-18 (CK-18) could be a marker of hepatocyte caspase-...